KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in IntangiblesChange in InventoryDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNTech SE (BNTX) Net Cash Flow (2018 - 2025)

Historic Net Cash Flow for BioNTech SE (BNTX) over the last 8 years, with Q3 2025 value amounting to -$182.5 million.

  • BioNTech SE's Net Cash Flow rose 7893.67% to -$182.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $516.6 million, marking a year-over-year increase of 11214.54%. This contributed to the annual value of -$2.1 billion for FY2024, which is 1928.28% up from last year.
  • As of Q3 2025, BioNTech SE's Net Cash Flow stood at -$182.5 million, which was up 7893.67% from $77.9 million recorded in Q2 2025.
  • In the past 5 years, BioNTech SE's Net Cash Flow ranged from a high of $5.0 billion in Q1 2022 and a low of -$2.9 billion during Q1 2024
  • Over the past 5 years, BioNTech SE's median Net Cash Flow value was $340.8 million (recorded in 2021), while the average stood at $632.3 million.
  • Its Net Cash Flow has fluctuated over the past 5 years, first skyrocketed by 6173782695.9% in 2021, then crashed by 31161.26% in 2023.
  • Over the past 5 years, BioNTech SE's Net Cash Flow (Quarter) stood at $342.5 million in 2021, then soared by 175.69% to $944.2 million in 2022, then tumbled by 311.61% to -$2.0 billion in 2023, then soared by 107.28% to $145.4 million in 2024, then plummeted by 225.48% to -$182.5 million in 2025.
  • Its Net Cash Flow was -$182.5 million in Q3 2025, compared to $77.9 million in Q2 2025 and $475.8 million in Q1 2025.